Editor\u2019s Take: Pancreatic cancer remains one of the most lethal cancers, with a five-year relative survival rate of just 13%.<\/p>\n
Novocure<\/a> announced a clinical trial collaboration and supply agreement with Verastem Oncology<\/a> targeting locally advanced pancreatic cancer.<\/p>\n The companies will use Novocure\u2019s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem\u2019s investigational KRAS G12D (ON\/OFF) inhibitor.<\/p>\n Novocure defines TTFields as electric fields exerting physical forces to kill cancer cells through various mechanisms. This does not significantly affect healthy cells as those have different properties\u2014division rate, morphology, electrical\u2014than cancer cells.<\/p>\n Pancreatic Cancer Stats<\/p>\n According to the World Health Organization, pancreatic cancer remains one of the most lethal cancers. In the United States, it accounts for the third-most frequent cause of cancer death; in Europe, fifth-most.<\/p>\n Pancreatic cancer\u2019s five-year relative survival rate is only 13%.<\/p>\n Verastem to Aid Novocure Trial<\/p>\n Novocure is planning a clinical trial in pancreatic cancer, using TTFields with gemcitabine, nab-paclitaxel, and VS-7375, in approximately 25 patients. As part of this new agreement, Novocure will manage and fund clinical trial operations.<\/p>\n As for Verastem\u2019s role, they will provide VS-7375 for the trial, which is expected to begin enrolling patients in 2027.<\/p>\n \u201cMeaningful progress has been made in [treating] pancreatic cancer,\u201d Novocure Chief Medical and Innovation Officer Uri Weinberg, MD, PhD, said. \u201cWe are proud that Tumor Treating Fields therapy is one of the new options available to patients. However, advanced pancreatic cancer remains one of the most difficult cancers to treat. We believe the physical modality of Tumor Treating Fields therapy, used with a KRAS inhibitor, has potential to be effective.\u201d<\/p>\n \u201cWe are excited to build on Novocure\u2019s work,\u201d Verastem President of Development Michael Kauffman, MD, PhD, said. \u201cThis collaboration will allow us to explore whether these treatment approaches, used together, can drive deeper and more durable responses.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Editor\u2019s Take: Pancreatic cancer remains one of the most lethal cancers, with a five-year relative survival rate of…\n","protected":false},"author":2,"featured_media":897978,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[4,450,451,3,452,453],"class_list":["post-897977","post","type-post","status-publish","format-standard","has-post-thumbnail","category-breaking-news","tag-breaking-news","tag-breakingnews","tag-headlines","tag-news","tag-top-stories","tag-topstories"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/897977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=897977"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/897977\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/897978"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=897977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=897977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=897977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}